

# Light controllable TiO<sub>2</sub>-Ru nanocomposite system **encapsulated in phospholipid unilamellar vesicles for anti‑cancer photodynamic therapy**

 $\mathbf{M}$ ilica $\mathbf{M}$ atijević $^{\mathbf{l}}\mathbf{\Phi}\cdot\mathbf{M}$ aja Nešić $^{\mathbf{l}}\cdot\mathbf{M}$ ilutin Stepić $^{\mathbf{l}}\cdot\mathbf{M}$ arija Radoičić $^{\mathbf{l}}\cdot\mathbf{M}$ **Zoran Šaponjić<sup>1</sup> · Marijana Petković1**

Received: 14 October 2017 / Accepted: 9 May 2018 / Published online: 22 May 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018

**Abstract** Photodynamic therapy implies a combined use of a photosensitizing medicament and low-intensity light to cause selective damage to the target tissue—tumor. As potential medicament, we use  $Ru(II)(dcbpy)<sub>2</sub>Cl<sub>2</sub>$  complex, and in order to achieve better photosensitization properties, the Ru complex was attached to the nano carrier—TiO<sub>2</sub> nanoparticles. Additionally, this nanocomposite system was encapsulated in the phospholipid vesicles, which could be classifed as small unilamellar vesicles, based on the technique of production. The complex-release tests were performed under light illumination, at pH 5, characteristic for tumor cells` interior and compared with the release pattern at pH 7, characteristic for the serum, i.e. physiological solution.

**Keywords** Photodynamic therapy · Light controlled drug release · Metallo-drug delivery

# **1 Introduction**

Photodynamic therapy represents an alternative tumor-ablative, function-sparing and cost-effective oncologic approach (Dougherty et al. [1998\)](#page-7-0). Usually, medicaments are delivered to diseased tissues by diferent types of carriers, which have the purpose to preserve medicament in the circulation and to minimize toxic side-efects (Hu et al. [2015](#page-7-1)). The light-induced medicament activation is based on the intrinsic optical properties of a medicament carrier and a medicament itself. In most cases, a nanoparticle (NP)-based medicament carrier or a

This article is part of the Topical Collection on Focus on Optics and Bio-photonics, Photonica 2017.

Guest Edited by Jelena Radovanovic, Aleksandar Krmpot, Marina Lekic, Trevor Benson, Mauro Pereira, Marian Marciniak.

 $\boxtimes$  Milica Matijević milica.m@vin.bg.ac.rs

<sup>&</sup>lt;sup>1</sup> Vinča Institute of Nuclear Sciences, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade 11 351, Serbia

medicament itself act as photosensitizers (PSs), by triggering free radical reactions in cells leading eventually to the cell death. As carriers, inorganic NPs have great potency for use, as they can act as PSs due to their distinctive optical absorption properties, transparency of the matrix to light absorption and chemical inertness. They can be easily attached to therapeutic medicament in the form of nanocomposite system (NCS), which can exhibit greater cytotoxicity (Nešić et al. [2017](#page-7-2)) and higher therapeutic efectiveness for cancer than the corresponding free drugs (Wang et al. [2015](#page-7-3); Chen et al. [2011](#page-7-4)).

We used  $TiO<sub>2</sub>$  NPs as carrier because of their availability, minimal dark cytotoxicity at low concentrations and brief exposure (Hou et al.  $2015$ ). TiO<sub>2</sub> NPs also showed great chemical stability and minimal impact to the environment (Zhang et al. [2012\)](#page-7-6). The photocatalytic killing effect to the tumor cells of the  $TiO<sub>2</sub>$  NPs had been confirmed, via the caspase-dependent apoptosis (Zhang et al. [2014\)](#page-7-7).

The surface of  $TiO<sub>2</sub>$  can be modified and thus specifically designed for the function of drug carriers (Wang et al. [2015](#page-7-3)). As the second component of the system,  $Ru(II)(dcbpy)_{2}Cl_{2}$  complex, that belongs to the second generation of metallo-drugs, can be easily attached to the TiO<sub>2</sub> surface via carboxyl groups (Savić et al.  $2012$ ), while the central metal ion remains free for the interaction with biomolecules. In the feld of the development of anticancer drugs, it was proved that some Ru complexes could promote the intracellular formation of free radical species upon irradiation, thus photosensitizing capacity for PDT had been confrmed (Levina et al. [2009](#page-7-9)). The photoactive properties of the  $Ru(II)(dcbpy)$ , Cl<sub>2</sub> complex had been confirmed in the nanocrystalline TiO<sub>2</sub>-based solar cell (Nazeeruddin et al. [1999\)](#page-7-10). Moreover, in our previous work we showed that this NCS which is conjugate of  $Ru(II)(dcbpy)_{2}Cl_{2}$  complex and TiO<sub>2</sub> NPs, has cytotoxic effect on melanoma cells (Nešić et al. [2017\)](#page-7-2), and that the complex release kinetics can be infuenced by light of various wavelengths. Additionally, the system demonstrated light-tunable properties, regarding the cell cytotoxicity: the melanoma cell cytotoxicity increased upon UV light illumination, whereas visible light reduced the number of dead melanoma cells (Nešić et al. [2017\)](#page-7-2).

In spite of initial success, there are several issues which are addressed in the present study. Firstly, the stability of the system in physiological conditions (for instance, stability in human sera during drug administration and transportation) is questionable, because there is the risk from the NCSs aggregation. Second question is whether is possible to afect the complex release properties when the system is encapsulated in the phospholipid vesicles, which should additionally prevent the complex leakage from the NCS, and potentially increase the cellular uptake of the NCS by tumor cells. To address the frst issue, we have stabilized colloidal dispersion of TiO<sub>2</sub> NPs in physiological conditions,  $pH$  7, by NP surface modification. Then, NCS was formed as described in our previous work (Nešić et al. [2016](#page-7-11), [2017](#page-7-2)), and binding of Ru-complex to the surface of the TiO<sub>2</sub> NPs was confirmed by Fourier transform infrared (FTIR) spectroscopy. Secondly, NCS was encapsulated in the small unilamellar vesicules (SUVs), and for both systems, encapsulated and non-encapsulated, visible light photo responsive properties for potential controlled drug delivery were examined.

# **2 Materials and methods**

#### **2.1 Synthesis and characterization of transitional metal complex and NCS**

Complex cis-dichlorobis(2,2'-bipyridyl-4,4'-dicarboxylic acid) ruthenium(II), was synthesized using the procedure described earlier (Nazeeruddin et al. [1999](#page-7-10)) and stored in the dark at −20 °C. Synthesized Ru(II) complex was characterized by UV–Vis spectrophotometry and by FTIR spectroscopy. Colloidal TiO<sub>2</sub> NPs pH 7 (d-5 nm) were synthesized by the slightly modifed method of Rajh et al. ([2004\)](#page-7-12).

Ethanol solution of complex was added to aqueous suspensions of  $TiO<sub>2</sub>$  NPs pH 7, estimating that the fraction of exposed Ti atoms on surface of TiO<sub>2</sub> NPs is  $30\%$  (Lin et al. [1997\)](#page-7-13). The reaction mixture was incubated overnight in the dark at room temperature for the preparation of NCS. The stability of the NCS was checked by additional incubation with Bovine Serum Albumin at physiological conditions (phosphate buffer saline, pH 7), that was followed by ultra-centrifugation with extreme G force of  $40,000 \times g$ , for 1 h (Beckman J2–21).

A commercial UV–Vis spectrometer (Perkin Elmer Lambda 35) was used for acquisition of the spectra of complex at room temperature. FTIR spectra of the synthesized complex and complex-TiO<sub>2</sub> NCS were recorded using Nicolet 380 FTIR spectrophotometer (Thermo Electron Corporation) in attenuated total refection (ATR) mode. For each spectrum, 64 scans were performed, with a resolution of cm−1, in the range of 400–4000 cm−1.

#### **2.2 Isolation of phospholipids and formation of SUVs**

For isolation and preparation of SUVs we used egg yolk phospholipids. The phospholipids were extracted by the procedure for total lipid extraction from the egg yolk (Furusawa et al. [1999\)](#page-7-14), and the phospholipids composition was confrmed by thin layer chromatography by the procedure described earlier (Davidson et al. [1998\)](#page-7-15). SUVs were prepared by the procedure that had been used for encapsulation of  $TiO<sub>2</sub>$  NPs (Alonso et al. [1982](#page-6-0)), and the literature suggests that SUVs had diameter of around 30 nm.

#### **2.3 Encapsulation of NCS in SUVs**

The specifc amount of formed NCS was additionally incubated overnight, with SUVs in 1:1 mass proportion, in dark and at room temperature. The SUV-NCS system that was formed was cross-examined, under identical conditions, as the free NCS.

#### **2.4 Light stimuli complex release studies**

To investigate the infuence of red and UV light on the rate of complex release from NPs, we performed two separate tests, with the identical principle—samples consisting of 750 µL NCS solution or SUVs-NCS (750 µL + 750 µL) was placed into the dialysis cassette (Thermo Scientifc Dialysis cassette, 7000 MWCO, 0.5–5 mL capacity). Then the cassettes were transferred into the beakers with 150 mL of phosphate bufer saline (PBS) solution. For these tests, we used PBS solutions with two pH level, pH 7 and pH 5. The samples were stirred in dark at room temperature, and for illumination we have applied the red light (the intensity of 80  $\mu$ W) and UV light (120  $\mu$ W). The source of red light was a CW He–Ne laser (Coherent, 2 mW, 632.8 nm) whereas we used UV light from UVC Hglamp (Philips, 25 W, 254 nm). The light intensities were measured with laser power meter NOVA II (Ophir) with UV enhanced silicon photodiode sensor PD300-UV with installed filter (CW power up to 300 mW). At the indicated time intervals, 500  $\mu$ L of samples were removed from outer medium and replaced with equal volumes of PBS solution, and the aliquots were analyzed by measuring absorbance at 310 nm, which was specifc for used complex. Concentration of drug released from composite matrix was calculated and plotted

against the time. Non-irradiated NCS complex release profle served as control, for both tests.

# **3 Results and discussion**

# **3.1 Characterization of transitional metal complex and complex-TiO<sub>2</sub> NCS**

The transitional complex,  $Ru(II)(dcbpy)_{2}Cl_{2}$ , was selected because of its binding potential for the surface of TiO<sub>2</sub>. This complex contains ligand with carboxyl groups, which has strong affinity for the TiO<sub>2</sub> NPs surface. To establish the end point of synthesis of the complex and binding of ligand to the  $RuCl<sub>3</sub>$  salts, we measured the relative intensities of the absorption maxima in 9 mM ethanol solution of the complex. The UV–Vis spectra of complex is shown in the Fig. [1a](#page-4-0), and the absorption maxima measured (I) correspond well to the data from literature (II), (Nazeeruddin et al. [1999\)](#page-7-10), and are presented in Table [1](#page-4-1).

Four carboxyl groups on the Ru-complex can coordinate the Ti atoms on the surface of TiO<sub>2</sub> NPs in three modes forming bidentate, unidentate and bridging carboxylates (Nazeeruddin et al. [2003\)](#page-7-16). In our previous work, we carried out surface modifcation of colloidal TiO<sub>2</sub> NPs (pH 3) with Ru complexes, discussed those binding options and concluded that in this system unidentate binding structure prevails (Nešić et al. [2017](#page-7-2)). Since the NCSs applied in this work were prepared by modifed synthetic approach taking care about fnal pH of dispersion (pH 7) and particles stability in physiological conditions, a slightly diferent interaction between colloidal TiO<sub>2</sub> NPs (pH 7) and Ru(II) complexes could be expected.

The ATR-FTIR spectra of powdered samples of Ru(II) complex and NCS (colloidal  $TiO<sub>2</sub>$  NPs (pH 7) surface modified by Ru(II) complex) are shown in Fig. [1](#page-4-0)b. In FTIR spectrum of Ru(II) complex peaks characteristic for stretching vibrations of carboxylic groups  $\nu_s$ (–COOH) at~1700 and~1540 cm<sup>-1</sup> were clearly observed as well as peaks assigned to stretching vibrations of  $\nu$ (CO) at 1215 and 1130 cm<sup>-1</sup>. Finally, strong peak at 1014 cm<sup>-1</sup> could be assigned to the deformation vibrations of carboxyl groups  $\delta$ (O–CO–H). In the FTIR spectrum of NCS all previously mentioned peaks are of reduced intensities indicating the possible interaction of  $Ru(II)$  complexes and surface of colloidal TiO<sub>2</sub> NPs (pH 7). More precisely, appearance of new peaks at 1590 and 1365 cm−1 in FTIR spectrum of NCS and a signifcant decrease in the intensity of a peak assigned to stretching vibration of carboxylic groups at 1700 cm−1, implied to the contribution of unidentate and bridging binding of Ru(II) complexes to an colloidal TiO<sub>2</sub> NPs (pH 7).

#### **3.2 Complex release tests**

In order to investigate the infuence of light on the kinetics of complex release, as possible ways to preserve the medicament before it reaches the target tissue, and the possibilities to control the release rates, we performed separate tests, for two type of samples—SUVs encapsulated NCS and free NCS, in which we irradiated samples with red (632.8 nm) and UVC (254 nm) light. Along with illumination experiments, control experiments were performed, i.e. the kinetics of a drug release in the dark. Additionally, two pH values of dialysis solutions were used for the study of complex release properties of NCS: PBS with pH 5, and PBS medium of pH 7. The SUV-NCS sample was dialysed only against the PBS medium of pH 7, since the liposomal encapsulation should prevent leaking of the model drug—complex before it reaches the target tissue, i.e. in the serum/circulation. All the



<span id="page-4-0"></span>**Fig. 1** UV-Vis spectra of complex  $Ru(II)(dcbpy)_{2}Cl_{2}$  (a). The FTIR spectrum of complex and NCS (**b**)

<span id="page-4-1"></span>

studies were carried out in triplicate. The schematic diagram of experimental setup for the sample illumination with red light of NCS in pH 7 and pH 5 medium, is shown in Fig. [2](#page-5-0), and obtained release curves from release tests are shown in Fig. [3](#page-6-1).

All nine drug release profles suggest a biphasic release process, with an initial burst phase followed by a lag period before the onset of degradation phase. At pH 7, the results obtained with red light illumination are as expected—the complex release rate is lower upon illumination of the NCS with red light. On the contrary, UV seems not to have any

infuence on the complex release rate. In contrast to the previous system, the surface of NPs used in this work is additionally modifed, it seems that either higher UV power is needed to achieve comparable efects, or that the mechanism of complex release is in the present case diferent.

Also, the results obtained at pH 5 are quite unexpected, because there are no diferences in the complex release rates in the dark and upon illumination. Apart from the unknown mechanism of the complex release when the surface of  $TiO<sub>2</sub>$  is modified, the difference in the release rate upon visible light illumination might also arise from the higher moiety of the protonated carboxylic acid residues, and hydration layer on the surface of  $TiO<sub>2</sub>$ , which prevent re-binding of the complex to the NPs` surface once they are released.

Encapsulation of NCS in SUVs showed that irradiation, either with red or UV light, had similar impact to the release rates, as under all experimental conditions, the complex release from the conjugate NCS-SUV was less than 60% of total bound complex. This experiment is only preliminary, but it is possible that phospholipids absorb a major part of the applied light, both UV and visible, which explains the similarity with results of control experiments.

## **4 Conclusion**

In this study we synthesized NCS which had shown promising light-controllable drugrelease ability. NCS prepared in this way was extremely stable under physiological conditions, which enables in vivo experiments in the future. We demonstrated that, due to the presence of the Ru-complex in physiological conditions, the system had the ability to respond to red light by sustaining complex release, whereas the encapsulation in SUVs showed the potency to additionally preserve complex from release before it reaches tumor cells. Sustained release could decrease side efects and increase efectiveness, so this property is strongly favorable for drug delivery systems, and makes this NCS interesting for further investigation. Greater impact of red light on the sustained complex release at pH 7, is the advantageous property, because it opens possibility to keep the complex bound to the surface of nanoparticle with red light until the system reaches target tissue.



<span id="page-5-0"></span>**Fig. 2** Schematic diagram of the experimental setup: HeNe red laser beam is split by glass cube beam splitter into two beams and refected by plane mirrors to the samples. The power of each beam is regulated by variable neutral density flter

<span id="page-6-1"></span>**Fig. 3** Comparative complex release profles of non-irradiated sample (annotated with "No irradiation"), samples irradiated with red light ("Vis-red light"), and samples irradiated with UV light ("UV light"). Briefy, the complex release test was carried out at the room temperature, and the system was monitored for 32 h. The complex release from the free NCS in the dissolution medium PBS of pH 7 is shown at **a** the complex release from the free NCS in the dissolution medium PBS of pH 5 is shown at **b** and the complex release from the conjugate SUV-NCS in the dissolution medium PBS of pH 7 is shown at **c**. The concentrations of the released complex are expressed as the percentage of the control experiments, i.e. of the free complex. Experiments are performed in triplicate and the mean $\pm$ SD are presented in graphs



**Acknowledgements** This work was funded by the Serbian Ministry of Education, Science and Technological Development, Grants OI 172011, OI 172056 and III 45010.

# **References**

<span id="page-6-0"></span>Alonso, A., Sáez, R., Villena, A., Goñi, F.M.: Increase in size of sonicated phospholipid vesicles in the presence of detergents. J. Membr. Biol. **67**, 55–62 (1982)

- <span id="page-7-4"></span>Chen, Y., Wan, Y., Wang, Y., Zhang, H., Jiao, Z.: Anticancer efficacy enhancement and attenuation of side efects of doxorubicin with titanium dioxide nanoparticles. Int. J. Nanomed. **6**, 2321–2326 (2011)
- <span id="page-7-15"></span>Davidson, W.S., Jonas, A., Clayton, D.F., George, J.M.: Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. **273**, 9443–9449 (1998)
- <span id="page-7-0"></span>Dougherty, T.J., Gomer, C.J., Henderson, B.W., Jori, G., Kessel, D., Korbelik, M., Moan, J., Peng, Q.: Photodynamic therapy. JNCI J. Natl. Cancer Inst. **90**, 889–905 (1998)
- <span id="page-7-14"></span>Furusawa, N., Ozaki, A., Nakamura, M., Morita, Y., Okazaki, K.: Simple and rapid extraction method of total egg lipids for determining organochlorine pesticides in the egg. J. Chromatogr. A **830**, 473–476 (1999)
- <span id="page-7-5"></span>Hou, Z., Zhang, Y., Deng, K., Chen, Y., Li, X., Deng, X., Cheng, Z., Lian, H., Li, C., Lin, J.: UV-emitting upconversion-based TiO<sub>2</sub> photosensitizing nanoplatform: near-infrared light mediated in vivo photodynamic therapy via mitochondria-involved apoptosis pathway. ACS Nano **9**, 2584–2599 (2015)
- <span id="page-7-1"></span>Hu, J., Tang, Y., Elmenoufy, A.H., Xu, H., Cheng, Z., Yang, X.: Nanocomposite-based photodynamic therapy strategies for deep tumor treatment. Mat. Views **11**, 5860–5887 (2015)
- <span id="page-7-9"></span>Levina, A., Mitra, A., Lay, P.A.: Recent developments in ruthenium anticancer drugs. Metallomics **1**, 458– 470 (2009)
- <span id="page-7-13"></span>Lin, X.C., Rajh, T., Zhiyu, W., Thurnauer, M.C.: XAFS studies of surface structures of TiO<sub>2</sub> nanoparticles and photocatalytic reduction of metal ions. J. Phys. Chem. B **101**, 10688–10697 (1997)
- <span id="page-7-10"></span>Nazeeruddin, M.K., Zakeeruddin, S.M., Humphry-Baker, R., Jirousek, M., Liska, P., Vlachopoulos, N., Shklover, V., Fischer, C.-H., Grätzel, M.: Acid-base equilibria of (2,2′-Bipyridyl-4,4′-dicarboxylicacid) ruthenium(II)} complexes and the efect of protonation on charge-transfer sensitization of nanocrystalline titania. Inorg. Chem. **38**, 6298–6305 (1999)
- <span id="page-7-16"></span>Nazeeruddin, M.K., Humphry-Baker, R., Liska, P., Grätzel, M.: Investigation of sensitizer adsorption and the influence of protons on current and voltage of a dye-sensitized nanocrystalline  $TiO<sub>2</sub>$  solar cell. J. Phys. Chem. B **107**, 8981–8987 (2003)
- <span id="page-7-11"></span>Nešić, M., Popović, I., Leskovac, A., Šaponjić, Z., Radoičić, M., Stepić, M., Petković, M.: Testing the photo-sensitive nanocomposite system for potential controlled metallo-drug delivery. Opt. Quantum Electron. **48**, 119–126 (2016)
- <span id="page-7-2"></span>Nešić, M., Žakula, J., Korićanac, L., Stepić, M., Radoičić, M., Popović, I., Šaponjić, Z., Petković, M.: Light controlled metallo-drug delivery system based on the  $TiO<sub>2</sub>-$  nanoparticles and Ru-complex. J. Photochem. Photobiol. A Chem. **347**, 55–66 (2017)
- <span id="page-7-12"></span>Rajh, T., Šaponjić, Z., Liu, J., Dimitrijević, N.M., Scherer, N.F., Arroyo, V.M., Zapol, P., Curtiss, L.A., Thurnauer, M.C.: Charge transfer across the nanocrystalline-DNA interface: probing DNA recognition. Nano Lett. **4**, 1017–1023 (2004)
- <span id="page-7-8"></span>Savić, T., Janković, I., Šaponjić, Z., Čomor, M., Veljković, D., Zarić, S., Nedeljković, J.: Surface modifcation of anatase nanoparticles with fused ring catecholate type ligands: a combined DFT and experimental study of optical properties. Nanoscale **4**, 1612–1619 (2012)
- <span id="page-7-3"></span>Wang, T., Jiang, H., Wan, L., Zhao, Q., Jiang, T., Wang, B., Wang, S.: Potential application of functional porous TiO<sub>2</sub> nanoparticles in light-controlled drug release and targeted drug delivery. Acta Biomater. **13**, 354–363 (2015)
- <span id="page-7-6"></span>Zhang, H., Wang, C., Chen, B., Wang, X.: Daunorubicin-TiO<sub>2</sub> nanocomposites as a "smart" pH-responsive drug delivery system. Int. J. Nanomedicine **7**, 235–242 (2012)
- <span id="page-7-7"></span>Zhang, H., Shan, Y., Dong, L.: A Comparison of  $TiO<sub>2</sub>$  and ZnO nanoparticles as photosensitizers in photodynamic therapy for cancer. J. Biomed. Nanotechnol. **10**, 1450–1457 (2014)